

Chapter 31

Regulation of the Production and Activation of Eosinophils

Kristin M. Leiferman, Lisa A. Beck, & Gerald J. Gleich

REFERENCES

1. Kita H, Adolphson CR, Gleich GJ: Biology of eosinophils. In: *Allergy: Principles and Practice*, 6 edition, edited by NF Jr. Adkinson, JW Yunginger, WW Busse, BS Bochner, ST Holgate, FER Simons. Philadelphia, Mosby, 2003, pp. 305-332
2. Blanchard C, Rothenberg ME: Biology of the eosinophil. *Adv Immunol* **101**:81-121, 2009
3. Hogan SP et al: Eosinophils: Biological properties and role in health and disease. *Clin Exp Allergy* **38**(5):709-750, 2008
4. Ackerman SJ, Bochner BS: Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. *Immunol Allergy Clin North Am* **27**(3):357-375, 2007.[PMCID: 2064859]
5. Denburg JA et al: Heterogeneity of human peripheral blood eosinophil-type colonies: Evidence for a common basophil-eosinophil progenitor. *Blood* **66**(2):312-318, 1985
6. Herrera-Goepfert R, Larraza-Hernandez O: [Hypereosinophilic syndrome]. *Bol Med Hosp Infant Mex* **42**(3):201-206, 1985
7. Marechaud R et al: [Hypereosinophilic syndrome: A new case of myeloproliferative type]. *Rev Med Intern* **6**(2):155-157, 1985
8. Gauvreau GM, Ellis AK, Denburg JA: Haemopoietic processes in allergic disease: Eosinophil/basophil development. *Clin Exp Allergy* **39**(9):1297-1306, 2009
9. Bochner BS, Gleich GJ: What targeting eosinophils has taught us about their role in diseases. *J Allergy Clin Immunol* **126**(1):16-25, quiz 6-7, 2010. [PMCID: 2902581]
10. Dent LA et al: Eosinophilia in transgenic mice expressing interleukin 5. *J Exp Med* **172**(5):1425-1431, 1990[PMCID: 2188679]
11. Lee NA et al: Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. *J Immunol* **158**(3):1332-1344, 1997
12. Asquith KL et al: The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. *J Immunol* **180**(2):1199-1206, 2008
13. Rothenberg ME, Hogan SP: The eosinophil. *Annu Rev Immunol* **24**:147-174, 2006
14. Lee JJ et al: Defining a link with asthma in mice congenitally deficient in eosinophils. *Science* **305**(5691):1773-1776, 2004
15. Gleich GJ, Adolphson CR, Leiferman KM. Eosinophils. In: *Inflammation, Basic Principles and Clinical Correlates*, edited by JI Gallin, IM Goldstein, R Snyderman. New York, Raven Press, 1992, pp. 663-700
16. Rothenberg ME et al: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. *N Engl J Med* **358**(12):1215-1228, 2008
17. Leung DYM: Immunopathology of atopic dermatitis. *Springer Semin Immunopathol* **13**:427-440, 1992
18. Dyer KD et al: Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. *J Immunol* **181**(6):4004-4009, 2008PMCID: 2680436
19. Bedi R et al: Human C/EBP-epsilon activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation. *Blood* **113**(2):317-327, 2009PMCID: 2615649
20. Adachi T, Alam R: The mechanism of IL-5 signal transduction. *Am J Physiol* **275**(3 Pt 1):C623-C633, 1998
21. Kouro T, Takatsu K: IL-5- and eosinophil-mediated inflammation: From discovery to therapy. *Int Immunol* **21**(12):1303-1309, 2009
22. Rajka G: Natural history and clinical manifestations of atopic dermatitis. *Clin Rev Allergy* **4**(1):3-26, 1986
23. Nagasawa M, Ohshiba A, Yata J: Effect of recombinant interleukin 5 on the generation of cytotoxic T cells (CTL). *Cell Immunol* **133**(2):317-326, 1991

24. McNagny K, Graf T: Making eosinophils through subtle shifts in transcription factor expression. *J Exp Med* **195**(11):F43-F47, 2002[PMCID: 2193544]
25. Hirasawa R et al: Essential and instructive roles of GATA factors in eosinophil development. *J Exp Med* **195**(11):1379-1386, 2002[PMCID: 2193540]
26. Yu C et al: Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. *J Exp Med* **195**(11):1387-1395, 2002
27. Yamaguchi Y et al: C/EBPbeta and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: Implication for C/EBPbeta activity in eosinophil gene expression. *Blood* **94**(4):1429-1439, 1999
28. Yamanaka R et al: Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. *Proc Natl Acad Sci USA* **94**(24):13187-13192, 1997[PMCID: 24284]
29. Du J et al: Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. *J Biol Chem* **277**(45):43481-43494, 2002
30. Lekstrom-Himes J, Xanthopoulos KG: CCAAT/enhancer binding protein epsilon is critical for effective neutrophil-mediated response to inflammatory challenge. *Blood* **93**(9):3096-3105, 1999
31. Abedin MJ et al: Potential roles of galectins in myeloid differentiation into three different lineages. *J Leukoc Biol* **73**(5):650-656, 2003
32. Lenzi HL et al: Immunological system and *Schistosoma mansoni*: Co-evolutionary immunobiology. What is the eosinophil role in parasite-host relationship? *Mem Inst Oswaldo Cruz* **92**(Suppl. 2):19-32, 1997
33. Williams TJ: The eosinophil enigma. *J Clin Invest* **113**(4):507-509, 2004[PMCID: 338272]
34. Gomes I et al: Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: Implications in fibrogenesis. *J Allergy Clin Immunol* **116**(4):796-804, 2005
35. Noguchi H et al: Tissue eosinophilia and eosinophil degranulation in orbital pseudotumor. *Ophthalmology* **98**(6):928-932, 1991
36. Piliponsky AM et al: Effects of eosinophils on mast cells: A new pathway for the perpetuation of allergic inflammation. *Mol Immunol* **38**(16-18):1369, 2002
37. Piliponsky AM et al: Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. *Blood* **101**(5):1898-1904, 2003
38. Kato M et al: Eosinophil infiltration and degranulation in normal human tissue. *Anat Rec* **252**(3):418-425, 1998
39. Throsby M et al: CD11c+ eosinophils in the murine thymus: Developmental regulation and recruitment upon MHC class I-restricted thymocyte deletion. *J Immunol* **165**(4):1965-1975, 2000
40. Maddox DE et al: Localization of a molecule immunohistochemically similar to eosinophil major basic protein in human placenta. *J Exp Med* **160**(1):29-41, 1984
41. Wagner JM et al: Analysis of pregnancy-associated major basic protein levels throughout gestation. *Placenta* **14**(6):671-681, 1993
42. Zhang J, Lathbury LJ, Salamonsen LA: Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium. *Biol Reprod* **62**(2):404-411, 2000
43. Gouon-Evans V, Pollard JW: Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. *Endocrinology* **142**(10):4515-4521, 2001
44. Neves JS et al: Eosinophil granules function extracellularly as receptor-mediated secretory organelles. *Proc Natl Acad Sci USA* **105**(47):18478-18483, 2008[PMCID: 2587599]
45. Butterworth AE: The eosinophil and its role in immunity to helminth infection. *Curr Top Microbiol Immunol* **77**:127-168, 1977
46. Ackerman SJ et al: Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of *Schistosoma mansoni*. *Am J Trop Med Hyg* **34**(4):735-745, 1985
47. Yoon J et al: Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. *J Immunol* **181**(4):2907-2915, 2008[PMCID: 2614918]
48. Reese TA et al: Chitin induces accumulation in tissue of innate immune cells associated with allergy. *Nature* **447**(7140):92-96, 2007[PMCID: 2527589]
49. Matsuwaki Y et al: Recognition of fungal protease activities induces cellular activation and eosinophil-derived neurotoxin release in human eosinophils. *J Immunol* **183**(10):6708-6716, 2009[PMCID: 2843542]

50. Yousefi S et al: Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat Med* **14**(9):949-953, 2008
51. Rosenberg HF, Domachowske JB: Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. *J Leukoc Biol* **70**(5):691-698, 2001
52. Davoine F et al: Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells. *J Allergy Clin Immunol* **122**(1):69-77, e1-e2, 2008
53. Freedman AR et al: Human immunodeficiency virus infection of eosinophils in human bone marrow cultures. *J Exp Med* **174**(6):1661-1664. [PMCID: 2119059]
54. Shi HZ et al: Lymph node trafficking and antigen presentation by endobronchial eosinophils. *J Clin Invest* **105**(7):945-953, 2000
55. Shi HZ: Eosinophils function as antigen-presenting cells. *J Leukoc Biol* **76**(3):520-527, 2004
56. van Rijt LS et al: Airway eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T cells. *J Immunol* **171**(7):3372-3378, 2003
57. Kita H: The eosinophil: a cytokine-producing cell? *J Allergy Clin Immunol* **97**(4):889-892, 1996
58. Lacy P, Moqbel R: Eosinophil cytokines. *Chem Immunol* **76**:134-155, 2000
59. MacKenzie JR et al: Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. *J Immunol* **167**(6):3146-3155, 2001
60. Yang D et al: Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. *J Exp Med* **205**(1):79-90, 2008
61. Adamko D, Lacy P, Moqbel R: Eosinophil function in allergic inflammation: From bone marrow to tissue response. *Curr Allergy Asthma Rep* **4**(2):149-158, 2004
62. Klion AD, Nutman TB: The role of eosinophils in host defense against helminth parasites. *J Allergy Clin Immunol* **113**(1):30-37, 2004
63. Ellyard JI, Simson L, Parish CR: Th2-mediated anti-tumour immunity: Friend or foe? *Tissue Antigens* **70**(1):1-11, 2007
64. Tancrede-Bohin E et al: Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. *Arch Dermatol* **140**(9):1057-1061, 2004
65. Takanami I, Takeuchi K, Gika M: Immunohistochemical detection of eosinophilic infiltration in pulmonary adenocarcinoma. *Anticancer Res* **22**(4):2391-2396, 2002
66. Nielsen HJ et al: Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. *J Pathol* **189**(4):487-495, 1999
67. Gleich GJ: The eosinophil and bronchial asthma: Current understanding. *J Allergy Clin Immunol* **85**(2):422-436, 1990
68. Gleich GJ, Jacoby DB, Fryer AD: Eosinophil-associated inflammation in bronchial asthma: A connection to the nervous system. *Int Arch Allergy Immunol* **107**(1-3):205-207, 1995
69. Gleich GJ, Kita H: Bronchial asthma: Lessons from murine models. *Proc Natl Acad Sci USA* **94**(6):2101-2102, 1997
70. Gleich GJ: Mechanisms of eosinophil-associated inflammation. *J Allergy Clin Immunol* **105**(4):651-663, 2000
71. Cheng JF et al: Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. *J Allergy Clin Immunol* **99**(5):683-692, 1997
72. Davis MD et al: Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. *J Allergy Clin Immunol* **112**(5):988-994, 2003
73. Gundel RH, Letts LG, Gleich GJ: Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. *J Clin Invest* **87**(4):1470-1473, 1991
74. Gleich GJ, Adolphson C: Bronchial hyperreactivity and eosinophil granule proteins. *Agents Actions Suppl* **43**:223-230, 1993
75. Leiferman KM, Gleich GJ: Hypereosinophilic syndrome: Case presentation and update. *J Allergy Clin Immunol* **113**(1):50-58, 2004
76. Leiferman KM, Peters MS, Gleich GJ: The eosinophil and cutaneous edema. *J Am Acad Dermatol* **15**(3):513-517, 1986
77. Gleich GJ et al: Episodic angioedema associated with eosinophilia. *N Engl J Med* **310**(25):1621-1626, 1984
78. Plager DA et al: Eosinophil ribonucleases and their cutaneous lesion-forming activity. *J Immunol* **183**(6):4013-4020, 2009[PMCID: 2852253]
79. Trocme SD et al: Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. *Invest Ophthalmol Vis Sci* **35**(7):3051-3056, 1994

80. Leitch VD et al: IL-5-overexpressing mice exhibit eosinophilia and altered wound healing through mechanisms involving prolonged inflammation. *Immunol Cell Biol* **87**(2):131-140, 2009
81. Wasmoen TL et al: Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. *J Biol Chem* **263**(25):12559-12563, 1988
82. Rohrbach MS et al: Activation of platelets by eosinophil granule proteins. *J Exp Med* **172**(4):1271-1274, 1990
83. Zabucchi G et al: Mutual influence between eosinophil peroxidase (EPO) and neutrophils: Neutrophils reversibly inhibit EPO enzymatic activity and EPO increases neutrophil adhesiveness. *Immunology* **69**(4):580-587, 1990[PMCID: 1385633]
84. Sur S et al: Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. *J Leukoc Biol* **63**(6):715-722, 1998
85. Hamann KJ et al: Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: Evidence for intronless coding sequences in the ribonuclease gene superfamily. *Genomics* **7**(4):535-546, 1990
86. Rosenberg HF, Dyer KD: Diversity among the primate eosinophil-derived neurotoxin genes: A specific C-terminal sequence is necessary for enhanced ribonuclease activity. *Nucleic Acids Res* **25**(17):3532-3536, 1997[PMCID: 146920]
87. Gordon MH: Remarks on Hodgkin's Disease: A pathogenic agent in the glands, and its application in diagnosis. *Br Med J* **1**(3771):641-644, 1933[PMCID: 2368286]
88. Rosenberg HF, Dyer KD, Domachowske JB: Respiratory viruses and eosinophils: Exploring the connections. *Antiviral Res* **83**(1):1-9, 2009[PMCID: 2741084]
89. Rosenberg HF, Dyer KD, Domachowske JB: Eosinophils and their interactions with respiratory virus pathogens. *Immunol Res* **43**(1-3):128-137, 2009[PMCID: 2777531]
90. Rosenberg HF: Eosinophil-derived neurotoxin / RNase 2: Connecting the past, the present and the future. *Curr Pharm Biotechnol* **9**(3):135-140, 2008[PMCID: 2680432]
91. Yang D et al: Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. *J Immunol* **173**(10):6134-6142, 2004[PMCID: 2847482]
92. Dyer KD, Handen JS, Rosenberg HF: The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes. *Genomics* **40**(2):217-221, 1997
93. Ackerman SJ et al: Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. *J Biol Chem* **277**(17):14859-1468, 2002
94. Ackerman SJ et al: Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. *J Immunol* **150**(2):456-468, 1993
95. Stahle-Backdahl M, Parks WC: 92-kD gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. *Am J Pathol* **142**(4):995-1000, 1993[PMCID: 1886874]
96. Stahle-Backdahl M et al: Expression of 92-kDa type IV collagenase mRNA by eosinophils associated with basal cell carcinoma. *J Invest Dermatol* **99**(4):497-503, 1992
97. Stahle-Backdahl M et al: 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. *J Clin Invest* **93**(5):2022-2030, 1994[PMCID: 294314]
98. Yagisawa M et al: Superoxide release and NADPH oxidase components in mature human phagocytes: Correlation between functional capacity and amount of functional proteins. *Biochem Biophys Res Commun* **228**(2):510-516, 1996
99. Bandeira-Melo C et al: Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. *J Exp Med* **196**(6):841-850, 2002[PMCID: 2194050]
100. Bandeira-Melo C, Bozza PT, Weller PF: The cellular biology of eosinophil eicosanoid formation and function. *J Allergy Clin Immunol* **109**(3):393-400, 2002
101. Feltenmark S et al: Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. *Proc Natl Acad Sci USA* **105**(2):680-685, 2008[PMCID: 2206596]
102. Cromwell O et al: IgG-dependent generation of platelet-activating factor by normal and low density human eosinophils. *J Immunol* **145**(11):3862-3868, 1990

103. Spencer LA et al: Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. *J Leukoc Biol* **85**(1):117-123, 2009[PMCID: 2626765]
104. Kobayashi H et al: Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. *Blood* **99**(6):2214-2220, 2002
105. Shen ZJ, Esnault S, Malter JS: The peptidyl-prolyl isomerase Pin1 regulates the stability of granulocyte-macrophage colony-stimulating factor mRNA in activated eosinophils. *Nat Immunol* **6**(12):1280-1287, 2005
106. Kita H et al: Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. *J Exp Med* **174**(3):745-748, 1991
107. Daugherty BL et al: Cloning, expression, and characterization of the human eosinophil eotaxin receptor. *J Exp Med* **183**(5):2349-2354, 1996[PMCID: 2192548]
108. Oliveira SH, Lukacs NW: The role of chemokines and chemokine receptors in eosinophil activation during inflammatory allergic reactions. *Braz J Med Biol Res* **36**(11):1455-1463, 2003
109. Fulkerson PC et al: A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. *Proc Natl Acad Sci U S A* **103**(44):16418-16423, 2006[PMCID: 1637597]
112. Tachimoto H, Ebisawa M, Bochner BS: Cross-talk between integrins and chemokines that influences eosinophil adhesion and migration. *Int Arch Allergy Immunol* **128**(Suppl. 1):18-20, 2002
113. Simon HU: Molecules involved in the regulation of eosinophil apoptosis. *Chem Immunol Allergy* **91**:49-58, 2006
114. Linch SN et al: Mouse eosinophils possess potent antibacterial properties in vivo. *Infect Immun* **77**(11):4976-4982, 2009[PMCID: 2772534]
115. Wong CK et al: Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. *Am J Respir Cell Mol Biol* **37**(1):85-96, 2007
116. Nagase H et al: Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. *J Immunol* **171**(8):3977-3982, 2003
117. Miike S, Kita H: Human eosinophils are activated by cysteine proteases and release inflammatory mediators. *J Allergy Clin Immunol* **111**(4):704-713, 2003
118. Munitz A et al: CD48 is an allergen and IL-3-induced activation molecule on eosinophils. *J Immunol* **177**(1):77-83, 2006
119. Elsner J et al: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. *Blood* **88**(12):4684-4693, 1996
120. Munitz A, Levi-Schaffer F: Eosinophils: 'New' roles for 'old' cells. *Allergy* **59**(3):268-275, 2004
121. Noguchi H et al: Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. *Am J Pathol* **140**(2):521-528, 1992
122. Costello RW et al: Eosinophils and airway nerves in asthma. *Histol Histopathol* **15**(3):861-868, 2000
123. Durcan N et al: Eosinophil-mediated cholinergic nerve remodeling. *Am J Respir Cell Mol Biol* 2006
124. Steinhoff M et al: Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J Neurosci* **23**(15):6176-6180, 2003
125. Bochner BS, Schleimer RP: The role of adhesion molecules in human eosinophil and basophil recruitment. *J Allergy Clin Immunol* **94**(3 Pt 1):427-438; quiz 439, 1994
126. Pazdrak K et al: Cross-talk between ICAM-1 and granulocyte-macrophage colony-stimulating factor receptor signaling modulates eosinophil survival and activation. *J Immunol* **180**(6):4182-4190, 2008
127. Wardlaw A: Eosinophil trafficking: New answers to old questions. *Clin Exp Allergy* **34**(5):676-679, 2004
128. Rosenberg HF, Phipps S, Foster PS: Eosinophil trafficking in allergy and asthma. *J Allergy Clin Immunol* **119**(6):1303-1310, quiz 1311-1312, 2007
129. Zimmermann N et al: Chemokines in asthma: Cooperative interaction between chemokines and IL-13. *J Allergy Clin Immunol* **111**(2):227-242, quiz 243, 2003
130. Munitz A et al: A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. *Blood* **111**(12):5694-5703, 2008
131. Bruijnzeel PL et al: Eosinophil migration in atopic dermatitis. I: Increased migratory responses to N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4. *J Invest Dermatol* **100**(2):137-142, 1993
132. Beck LA et al: Cutaneous injection of RANTES causes eosinophil recruitment: Comparison of nonallergic and allergic human subjects. *J Immunol* **159**(6):2962-2972, 1997

133. Wedi B et al: Delayed eosinophil programmed cell death in vitro: A common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. *J Allergy Clin Immunol* **100**(4):536-543, 1997
134. Flood-Page PT et al: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. *Am J Respir Crit Care Med* **167**(2):199-204, 2003
135. Hogan SP: Recent advances in eosinophil biology. *Int Arch Allergy Immunol* **143**(Suppl. 1):3-14, 2007
136. Mehregan DR et al: Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. *Arch Dermatol* **128**(8):1055-1059, 1992
137. Lee SC et al: Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. *J Immunol* **164**(6):3392-3401, 2000
138. Baggiolini M, Dahinden CA: CC chemokines in allergic inflammation. *Immunol Today* **15**(3):127-133, 1994
139. Shahabuddin S, Ponath P, Schleimer RP: Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines. *J Immunol* **164**(7):3847-3854, 2000
140. Ponath PD et al: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. *J Exp Med* **183**(6):2437-2448, 1996[PMCID: 2192612]
141. Dulkys Y et al: Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils. *J Invest Dermatol* **116**(4):498-505, 2001
142. Ahrens R et al: Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. *J Immunol* **181**(10):7390-7399, 2008[PMCID: 2728352]
143. Mishra A et al: Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. *J Clin Invest* **103**(12):1719-1727, 1999[PMCID: 408388]
144. Rankin SM, Conroy DM, Williams TJ: Eotaxin and eosinophil recruitment: Implications for human disease. *Mol Med Today* **6**(1):20-27, 2000
145. Katoh S et al: Involvement of Galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. *Int Arch Allergy Immunol* **153**(3):294-302, 2010
146. Matsumoto R et al: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. *J Biol Chem* **273**(27):16976-16984, 1998
147. Igawa K et al: Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: Possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation. *Allergy* **61**(12):1385-1391, 2006
148. Kagami S et al: Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. *Clin Exp Immunol* **134**(2):309-313, 2003
149. O'Reilly M et al: Identification of a histamine H4 receptor on human eosinophils—role in eosinophil chemotaxis. *J Recept Signal Transduct Res* **22**(1-4):431-448, 2002
150. Blanchard C et al: Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. *Mucosal Immunol* **1**(4):289-296, 2008[PMCID: 2683986]
151. Horie S, Kita H: CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. *J Immunol* **152**(11):5457-5467, 1994
152. Matsumoto K et al: CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. *Am J Respir Cell Mol Biol* **18**(6):860-866, 1998
153. Dvorak AM et al: Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein. *Am J Pathol* **138**(1):69-82, 1991
154. Lacy P et al: Rapid mobilization of intracellularly stored RANTES in response to interferon-gamma in human eosinophils. *Blood* **94**(1):23-32, 1999
155. Bandeira-Melo C et al: EliCell: A gel-phase dual antibody capture and detection assay to measure cytokine release from eosinophils. *J Immunol Methods* **244**(1-2):105-115, 2000
156. Logan MR et al: Expression of eosinophil target SNAREs as potential cognate receptors for vesicle-associated membrane protein-2 in exocytosis. *J Allergy Clin Immunol* **109**(2):299-306, 2002

157. Logan MR et al: A critical role for vesicle-associated membrane protein-7 in exocytosis from human eosinophils and neutrophils. *Allergy* **61**(6):777-784, 2006
158. Schwiebert LM et al: Glucocorticosteroid inhibition of cytokine production: Relevance to antiallergic actions. *J Allergy Clin Immunol* **97**(1 Pt 2):143-152, 1996
159. Schleimer RP, Bochner BS: The effects of glucocorticoids on human eosinophils. *J Allergy Clin Immunol* **94**(6 Pt 2):1202-1213, 1994
160. Umland SP, Schleimer RP, Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. *Pulm Pharmacol Ther* **15**(1):35-50, 2002
161. Barnes PJ, Adcock IM: Steroid resistance in asthma. *QJM* **88**(7):455-468, 1995
162. Hunt LW et al: Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study. *J Allergy Clin Immunol* **113**(5):853-859, 2004
163. Hunt LW, Swedlund HA, Gleich GJ: Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. *Mayo Clin Proc* **71**(4):361-368, 1996
164. Bankers-Fulbright JL et al: Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. *J Immunol* **160**(11):5546-5553, 1998
165. Park CW et al: Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. *Br J Dermatol* **152**(6):1173-1181, 2005
166. Meng Q et al: Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival. *Allergy* **52**(11):1095-1101, 1997
167. Bai JP, Lesko LJ, Burckart GJ: Understanding the genetic basis for adverse drug effects: The calcineurin inhibitors. *Pharmacotherapy* **30**(2):195-209, 2010
168. Klion AD: Approach to the therapy of hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):551-560, 2007
169. Cools J et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* **348**(13):1201-1214, 2003
170. Pitini V et al: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: A case report. *Br J Haematol* **127**(5):477, 2004
171. Sefcick A et al: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. *Br J Haematol* **124**(4):558-559, 2004
172. Wagner LA et al: Treatment of FIP1L1/PDGFRAnegative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. *J Allergy Clin Immunol* **123**(6):1407-1408, 2009
173. Butterfield JH: Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. *Acta Haematol* **114**(1):26-40, 2005
174. Butterfield JH: Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. *Immunol Allergy Clin North Am* **27**(3):493-518, 2007
175. Kane GC et al: A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. *J Allergy Clin Immunol* **97**(2):646-654, 1996
176. Ellis E, Scheinfeld N: Eosinophilic pustular folliculitis: A comprehensive review of treatment options. *Am J Clin Dermatol* **5**(3):189-197, 2004
177. Sivasankaran S, Harikrishnan S, Tharakan JM: Left ventricular thrombi in the presence of normal left ventricular function. *Indian Heart J* **54**(2):196-198, 2002
178. Ota T et al: Eosinophilic pustular folliculitis (Ofuji's disease): Indomethacin as a first choice of treatment. *Clin Exp Dermatol* **26**(2):179-181, 2001
179. Quemeneur T et al: [Ofuji's papuloerythroderma: two cases treated with azathioprine]. *Ann Dermatol Venereol* **129**(2):213-215, 2002
180. Rand TH et al: Nedocromil sodium and cromolyn (sodium cromoglycate) selectively inhibit antibody-dependent granulocyte-mediated cytotoxicity. *Int Arch Allergy Appl Immunol* **87**(2):151-158, 1988
181. Snyman JR et al: Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: A comparative study. *Eur J Clin Pharmacol* **42**(4):359-362, 1992
182. Schaper C et al: Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis. *J Investig Allergol Clin Immunol* **19**(6):459-464, 2009
183. Abdelaziz MM et al: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. *J Allergy Clin Immunol* **101**(3):410-420, 1998
184. Haldar P et al: Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* **360**(10):973-984, 2009

185. Nair P et al: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. *N Engl J Med* **360**(10):985-993, 2009
186. Kahn JE et al: Sustained response to mepolizumab in refractory Churg-Strauss syndrome. *J Allergy Clin Immunol* **125**(1):267-270, 2010
187. Kim S et al: Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. *J Allergy Clin Immunol* **125**(6):1336-1343, 2010
188. Ogbogu PU et al: Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. *J Allergy Clin Immunol* **124**(6):1319-1325, e3, 2009[PMCID: 2829669]
189. Reed J et al: MEDI-563, a humanized anti-IL5Ra antibody with enhanced effector function, induces reversible blood eosinopenia in mild asthmatics. *J Allergy Clin Immunol* **121** (Suppl.):S47, 2008
190. Blanchard C et al: Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). *Clin Exp Allergy* **35**(8):1096-1103, 2005
191. Sehmi R, Baatjes AJ, Denburg JA: Hemopoietic progenitor cells and hemopoietic factors: Potential targets for treatment of allergic inflammatory diseases. *Curr Drug Targets Inflamm Allergy* **2**(4):271-278, 2003
192. Cowden JM et al: The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. *J Invest Dermatol* **130**(4):1023-1033, 2010
193. Thurmond RL, Gelfand EW, Dunford PJ: The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. *Nat Rev Drug Discov* **7**(1):41-53, 2008
194. Wong CK et al: Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: Implications in allergic inflammation. *Am J Respir Cell Mol Biol* **43**(3):305-315, 2010
195. Roviezzo F et al: Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. *Proc Natl Acad Sci USA* **101**(30):11170-11175, 2004[PMCID: 503758]
196. Sugita K et al: FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice. *Am J Pathol* **177**(4):1881-1887, 2010[PMCID: 2947283]
197. Munitz A et al: CD48 is critically involved in allergic eosinophilic airway inflammation. *Am J Respir Crit Care Med* **175**(9):911-918, 2007[PMCID: 1899297]
198. Nutku E et al: Ligation of Siglec-8: A selective mechanism for induction of human eosinophil apoptosis. *Blood* **101**(12):5014-5020, 2003
199. Park YM, Bochner BS: Eosinophil survival and apoptosis in health and disease. *Allergy Asthma Immunol Res* **2**(2):87-101, 2010[PMCID: 2846745]
200. Takatsu K, Kouro T, Nagai Y: Interleukin 5 in the link between the innate and acquired immune response. *Adv Immunol* **101**:191-236, 2009
201. Chen KR et al: Recurrent cutaneous necrotizing eosinophilic vasculitis. A novel eosinophil-mediated syndrome. *Arch Dermatol* **130**(9):1159-1166, 1994